title: Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
abstract: Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro. Recently, however, an R155K protease mutation was reported as the dominant quasispecies in a treatment-naïve individual, raising concerns about possible full drug resistance. To investigate the prevalence of dominant resistance mutations against specifically targeted antiviral therapy for HCV (STAT-C) in the population, we analyzed HCV genome sequences from 507 treatment-naïve patients infected with HCV genotype 1 from the United States, Germany, and Switzerland. Phylogenetic sequence analysis and viral load data were used to identify the possible spread of replication-competent, drug-resistant viral strains in the population and to infer the consequences of these mutations upon viral replication in vivo. Mutations described to confer resistance to the protease inhibitors Telaprevir, BILN2061, ITMN-191, SCH6 and Boceprevir; the NS5B polymerase inhibitor AG-021541; and to the NS4A antagonist ACH-806 were observed mostly as sporadic, unrelated cases, at frequencies between 0.3% and 2.8% in the population, including two patients with possible multidrug resistance. Collectively, however, 8.6% of the patients infected with genotype 1a and 1.4% of those infected with genotype 1b carried at least one dominant resistance mutation. Viral loads were high in the majority of these patients, suggesting that drug-resistant viral strains might achieve replication levels comparable to nonresistant viruses in vivo.
  
  
  CONCLUSIONS
  Naturally occurring dominant STAT-C resistance mutations are common in treatment-naïve patients infected with HCV genotype 1. Their influence on treatment outcome should further be characterized to evaluate possible benefits of drug resistance testing for individual tailoring of drug combinations when treatment options are limited due to previous nonresponse to peginterferon and ribavirin.
authors.affiliation: Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. t.kuntzen@gmx.de
authors.forename: Thomas
authors.initials: T
authors.lastname: Kuntzen
authors.forename: Joerg
authors.initials: J
authors.lastname: Timm
authors.forename: Andrew
authors.initials: A
authors.lastname: Berical
authors.forename: Niall
authors.initials: N
authors.lastname: Lennon
authors.forename: Aaron M
authors.initials: AM
authors.lastname: Berlin
authors.forename: Sarah K
authors.initials: SK
authors.lastname: Young
authors.forename: Bongshin
authors.initials: B
authors.lastname: Lee
authors.forename: David
authors.initials: D
authors.lastname: Heckerman
authors.forename: Jonathan
authors.initials: J
authors.lastname: Carlson
authors.forename: Laura L
authors.initials: LL
authors.lastname: Reyor
authors.forename: Marianna
authors.initials: M
authors.lastname: Kleyman
authors.forename: Cory M
authors.initials: CM
authors.lastname: McMahon
authors.forename: Christopher
authors.initials: C
authors.lastname: Birch
authors.forename: Julian
authors.initials: J
authors.lastname: Schulze Zur Wiesch
authors.forename: Timothy
authors.initials: T
authors.lastname: Ledlie
authors.forename: Michael
authors.initials: M
authors.lastname: Koehrsen
authors.forename: Chinnappa
authors.initials: C
authors.lastname: Kodira
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Roberts
authors.forename: Georg M
authors.initials: GM
authors.lastname: Lauer
authors.forename: Hugo R
authors.initials: HR
authors.lastname: Rosen
authors.forename: Florian
authors.initials: F
authors.lastname: Bihl
authors.forename: Andreas
authors.initials: A
authors.lastname: Cerny
authors.forename: Ulrich
authors.initials: U
authors.lastname: Spengler
authors.forename: Zhimin
authors.initials: Z
authors.lastname: Liu
authors.forename: Arthur Y
authors.initials: AY
authors.lastname: Kim
authors.forename: Yanming
authors.initials: Y
authors.lastname: Xing
authors.forename: Arne
authors.initials: A
authors.lastname: Schneidewind
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Madey
authors.forename: Jaquelyn F
authors.initials: JF
authors.lastname: Fleckenstein
authors.forename: Vicki M
authors.initials: VM
authors.lastname: Park
authors.forename: James E
authors.initials: JE
authors.lastname: Galagan
authors.forename: Chad
authors.initials: C
authors.lastname: Nusbaum
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Walker
authors.forename: Gerond V
authors.initials: GV
authors.lastname: Lake-Bakaar
authors.forename: Eric S
authors.initials: ES
authors.lastname: Daar
authors.forename: Ira M
authors.initials: IM
authors.lastname: Jacobson
authors.forename: Edward D
authors.initials: ED
authors.lastname: Gomperts
authors.forename: Brian R
authors.initials: BR
authors.lastname: Edlin
authors.forename: Sharyne M
authors.initials: SM
authors.lastname: Donfield
authors.forename: Raymond T
authors.initials: RT
authors.lastname: Chung
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Talal
authors.forename: Tony
authors.initials: T
authors.lastname: Marion
authors.forename: Bruce W
authors.initials: BW
authors.lastname: Birren
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Henn
authors.forename: Todd M
authors.initials: TM
authors.lastname: Allen
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002219:Carbamates / Q000494:pharmacology / Q000627:therapeutic use; D015331:Cohort Studies; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005820:Genetic Testing; D016174:Hepacivirus / Q000201:enzymology* / Q000235:genetics / Q000472:pathogenicity; D006526:Hepatitis C / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D047028:Macrocyclic Compounds / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009154:Mutation / Q000235:genetics*; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use; D010670:Phenylthiourea / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D010802:Phylogeny; D011392:Proline / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use; D019562:Viral Load; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D047028:Macrocyclic Compounds; D009842:Oligopeptides; D010670:Phenylthiourea; D011392:Proline; D011480:Protease Inhibitors; D011804:Quinolines; D013844:Thiazoles; D017361:Viral Nonstructural Proteins; C530651:1-(4-pentyloxy-3-trifluoromethylphenyl)-3-(pyridine-3-carbonyl)thiourea; C479555:BILN 2061; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C510133:SCH6; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase